Chemical Science · 2015 · 85 citations · 53 references
MedicineImmunologyOncologyCancer ImmunologyVaccine ImmunologyVaccinologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesConjugate VaccinesImmunotherapy For Breast CancerVaccine PlatformsCancer Vaccine T-cell ResponsesSelf-adjuvanting VaccinesSynthetic VaccineT-cell ImmunogenicityT-cell Mediated ImmunityTumor Antigen VaccinesTumor-associated Antigen VaccinesVaccine-induced T Cell Immunity
Therapeutic cancer vaccines based on the abnormal glycans expressed on cancer cells, such as the globo H antigen, have witnessed great progress in recent years. For example, the keyhole limpet hemocyanin (KLH) conjugate of globo H has been on clinical trials as a cancer vaccine. However, such vaccines have intrinsic problems, such as inconsistence in eliciting T cell-mediated immunity in cancer patients and difficult quality control. To address the issue, a structurally defined fully synthetic glycoconjugate vaccine composed of globo H and monophosphoryl lipid A (MPLA) was developed. The new vaccine was shown to elicit robust IgG1 antibody responses and T cell-dependent immunity, which is desired for anticancer vaccine, and induce significantly faster and stronger immune responses than the globo H-KLH conjugate. Moreover, it was self-adjuvanting, namely, inducing immune responses without the use of an external adjuvant, thus MPLA was not only a vaccine carrier but also a build-in adjuvant. It was also found that antibodies induced by the new vaccine could selectively bind to and mediate strong complement-dependent cytotoxicity to globo H-expressing MCF-7 cancer cell. All of the results have demonstrated that the globo H-MPLA conjugate is a better cancer vaccine than the globo H-KLH conjugate under experimental conditions and is worth further investigation and development.
53
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Beom Seok Park, Dong Hyun Song, Ho Min Kim et al. · Nature · 2009 · 2.4K citations
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Ho Min Kim, Beom Seok Park, Jung-In Kim et al. · Cell · 2007 · 1.2K citations · Full text
Reiji Kannagi, Nancy A. Cochran, Fumitsugu Ishigami et al. · The EMBO Journal · 1983 · 544 citations · Full text